PMID- 37544035
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230816
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 36
DP  - 2023 Oct
TI  - Long noncoding RNA BBOX1-AS1 increased radiotherapy sensitivity in colorectal 
      cancer by stabilizing and activating PFK1.
PG  - 101751
LID - S1936-5233(23)00137-7 [pii]
LID - 10.1016/j.tranon.2023.101751 [doi]
LID - 101751
AB  - PURPOSE: Our study explored the effect of long noncoding RNA BBOX1-AS1 on 
      colorectal cancer (CRC) radiosensitivity in vivo and in vitro. METHODS: 
      Differentially expressed lncRNAs in CRC were screened using a bioinformatics 
      database and an online prediction website. The expression of BBOX1-AS1 in tissue 
      samples was analyzed via real-time quantitative PCR (RT-qPCR). Subcellular 
      localization of BBOX1-AS1 in CRC cells was analyzed using fluorescence in situ 
      hybridization (FISH). The correlation between BBOX1-AS1 and PFK1 expression 
      levels in CRC tissues was analyzed via Pearson's correlation coefficient. The 
      effect of BBOX1-AS1 on PFK1 stability was investigated using RNA and protein 
      stability testing. RNA Binding Protein Immunoprecipitation (RIP) and RNA 
      pull-down assays were used to confirm the binding of BBOX1-AS1 to PFK1. RESULTS: 
      BBOX1-AS1 was highly expressed in CRC and associated with poor prognosis. 
      Similarly, it was highly expressed in CRC tissues and CRC cell lines. In 
      addition, BBOX1-AS1 promoted the proliferation, invasion, migration, and 
      glycolysis of CRC cells and inhibited apoptosis. RIP and RNA pull-down 
      experiments confirmed that BBOX1-AS1 bound to PFK1. RNA stability and protein 
      stability experiments showed that BBOX1-AS1 affected the stability of PFK1 mRNA 
      and protein. Furthermore, we confirmed that BBOX1-AS1 increased radiation 
      resistance through the regulation of PFK1 expression. CONCLUSIONS: BBOX1-AS1 
      promoted the proliferation, invasion, migration, and glycolysis of CRC cells 
      through stabilization of the expression of PFK1. BBOX1-AS1 also inhibited CRC 
      cell apoptosis and increased radiotherapy resistance in CRC cells.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China.
FAU - Li, Xiao-Fei
AU  - Li XF
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China; The Second Affiliated Hospital of Chengdu Medical 
      College (China National Nuclear Corporation 416 Hospital) , Chengdu, 610051, 
      Sichuan, China.
FAU - Zhou, Ying-Hui
AU  - Zhou YH
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China.
FAU - Qin, Xiang-Hong
AU  - Qin XH
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China.
FAU - Wang, Li-Hui
AU  - Wang LH
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China.
FAU - Xiao, Meng-Qing
AU  - Xiao MQ
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China.
FAU - Cao, Ke
AU  - Cao K
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China.
FAU - Ma, John K
AU  - Ma JK
AD  - Cotton O'Neil Cancer Center, Stormont Vail Hospital, Topeka, KS, USA.
FAU - Huang, Cheng-Hui
AU  - Huang CH
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha 410013, Hunan, China. Electronic address: hchdoctor@sohu.com.
LA  - eng
PT  - Journal Article
DEP - 20230804
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC10423889
OTO - NOTNLM
OT  - BBOX1-AS1
OT  - Colo205 cells
OT  - Colorectal cancer
OT  - HCT116 cells
OT  - Phosphofructokinase-1
OT  - Radiotherapy
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/08/06 19:15
MHDA- 2023/08/06 19:16
PMCR- 2023/08/04
CRDT- 2023/08/06 18:00
PHST- 2023/03/20 00:00 [received]
PHST- 2023/06/12 00:00 [revised]
PHST- 2023/07/28 00:00 [accepted]
PHST- 2023/08/06 19:16 [medline]
PHST- 2023/08/06 19:15 [pubmed]
PHST- 2023/08/06 18:00 [entrez]
PHST- 2023/08/04 00:00 [pmc-release]
AID - S1936-5233(23)00137-7 [pii]
AID - 101751 [pii]
AID - 10.1016/j.tranon.2023.101751 [doi]
PST - ppublish
SO  - Transl Oncol. 2023 Oct;36:101751. doi: 10.1016/j.tranon.2023.101751. Epub 2023 
      Aug 4.